Focal Seals FDA Panel Approval Recommendation For Lung Surgery Sealant
This article was originally published in The Gray Sheet
Executive Summary
Focal, Inc. should include a warning in labeling for FocalSeal-L synthetic lung surgery sealant that higher risks of infection or empyema may be associated with use of the product, FDA's General and Plastic Surgery Devices Advisory Panel recommended at a May 8 meeting in Gaithersburg, Maryland.
You may also be interested in...
Fusion Looking To Enter Cranial Surgery Sealant Market With Proceed Gel
Fusion Medical sees a $35 mil. market opportunity for the cranial indication of the firm's Proceed hemostatic sealant, based on a projected per-kit price of $140 and more than 240,000 cranial procedures performed worldwide annually.
Fusion Looking To Enter Cranial Surgery Sealant Market With Proceed Gel
Fusion Medical sees a $35 mil. market opportunity for the cranial indication of the firm's Proceed hemostatic sealant, based on a projected per-kit price of $140 and more than 240,000 cranial procedures performed worldwide annually.
Genzyme Leveraging Sales Force To Promote Focal FocalSeal-L Lung Sealant
Genzyme Surgical will use its existing sales force to distribute Focal's FocalSeal-L surgical lung sealant in the U.S. The product began shipping immediately following FDA's May 30 approval.